19q13 Amplification is associated with high grade and stage in pancreatic cancer

Genes Chromosomes and Cancer

Volumn 49, Issue 6, 2010, Pages 569-575

  Kuuselo, Riina ^a   Simon, Ronald ^c   Karhu, Ritva ^b   Tennstedt, Pierre ^c   Marx, Andreas H ^c   Izbicki, Jakob R ^c   Yekebas, Emre ^c   Sauter, Guido ^c   Kallioniemi, Anne ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 19; DNA COPY NUMBER VARIATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 77952038006     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20767     Document Type: Article

References (34)

1. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N, Cauwels C, Cordon-Cardo C, Redston MS, DePinho RA, Chin L. 2004. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 101:9067-9072. (Pubitemid 38781612)
2. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22:447-455.
3. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G. 2004. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534-8540. (Pubitemid 39552065)
4. Andersen CL, Hostetter G, Grigoryan A, Sauter G, Kallioniemi A. 2001. Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 45:83-86. (Pubitemid 32954237)
5. Bardi G, Johansson B, Pandis N, Mandahl N, Bak-Jensen E, Lindstrom C, Tornqvist A, Frederiksen H, Andren-Sandberg A, Mitelman F. 1993. Cytogenetic analysis of 52 colorectal carcinomas - Non-random aberration pattern and correlation with pathologic parameters. Int J Cancer 55:422-428. (Pubitemid 23300593)
6. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, Tibshirani R, Maitra A, Pollack JR. 2005. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7:556-562. (Pubitemid 40967756)
7. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V. 1995. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280-285.
8. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289.
9. Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-Ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R. 2008. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther 7.
10. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR. 1992. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89:9267-9271.
11. Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E. 2006. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res 66:4149-4158.
12. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G. 1998. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4:2383-2390. (Pubitemid 28477903)
13. Fletcher JA. 1999. DNA in situ hybridization as an adjunct in tumor diagnosis. Am J Clin Pathol 112:S11-S18.
14. Gysin S, Rickert P, Kastury K, McMahon M. 2005. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer 44:37-51. (Pubitemid 41060195)
15. Heidenblad M, Lindgren D, Veltman JA, Jonson T, Mahlamaki EH, Gorunova L, van Kessel AG, Schoenmakers EF, Hoglund M. 2005. Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene 24:1794-1801. (Pubitemid 40461135)
16. Hodgson JG, Chin K, Collins C, Gray JW. 2003. Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 78:337-345. (Pubitemid 36543213)
17. Holzmann K, Kohlhammer H, Schwaenen C, Wessendorf S, Kestler HA, Schwoerer A, Rau B, Radlwimmer B, Dohner H, Lichter P, Gress T, Bentz M. 2004. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res 64:4428-4433. (Pubitemid 38856913)
18. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM. 1994. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91:2156-2160. (Pubitemid 24092062)
19. Kim TM, Yim SH, Lee JS, Kwon MS, Ryu JW, Kang HM, Fiegler H, Carter NP, Chung YJ. 2005. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 11:8235-8242. (Pubitemid 41746932)
20. Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A. 2007. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 67:1943-1949. (Pubitemid 46424210)
21. Kwei KA, Bashyam MD, Kao J, Ratheesh R, Reddy EC, Kim YH, Montgomery K, Giacomini CP, Choi YL, Chatterjee S, Karikari CA, Salari K, Wang P, Hernandez-Boussard T, Swarnalata G, van de Rijn M, Maitra A, Pollack JR. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. 2008. PLoS Genet 4:e1000081. (Pubitemid 351793793)
22. Laurila E, Savinainen K, Kuuselo R, Karhu R, Kallioniemi A. 2009. Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. Genes Chromosomes Cancer 48:330-339.
23. Mahlamäki EH, Bärlund M, Tanner M, Gorunova L, Höglund M, Karhu R, Kallioniemi A. 2002. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35:353-358. (Pubitemid 35246993)
24. Mahlamäki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. 2004. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 6:432-439. (Pubitemid 39411079)
25. Moniaux N, Nemos C, Schmied BM, Chauhan SC, Deb S, Morikane K, Choudhury A, Vanlith M, Sutherlin M, Sikela JM, Hollingsworth MA, Batra SK. 2006. The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. Oncogene 25:3247-3257. (Pubitemid 43846309)
26. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty VV. 2004. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 4:5. (Pubitemid 38851368)
27. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G. 2000. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157:787-794. (Pubitemid 32109371)
28. Ried T, Petersen I, Holtgreve-Grez H, Speicher MR, Schrock E, du Manoir S, Cremer T. 1994. Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. Cancer Res 54:1801-1806.
29. Savelyeva L, Schwab M. 2001. Amplification of oncogenes revisited: From expression profiling to clinical application. Cancer Lett 167:115-123. (Pubitemid 32706673)
30. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. 2002. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8:1720-1730. (Pubitemid 34633727)
31. Staal SP. 1987. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84:5034-5037.
32. Tang TC, Sham JS, Xie D, Fang Y, Huo KK, Wu QL, Guan XY. 2002. Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13.1 in ovarian cancer cell lines. Cancer Res 62:7157-7161. (Pubitemid 36025229)
33. Thompson FH, Nelson MA, Trent JM, Guan XY, Liu Y, Yang JM, Emerson J, Adair L, Wymer J, Balfour C, Massey K, Weinstein R, Alberts DS, Taetle R. 1996. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet 87:55-62.
34. vanHattem WA, Carvalho R, Li A, Offerhaus GJ, Goggins M. 2008. Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Exp Pathol 1:343-351.